About this episode
Alphabet shares are falling today after a downgrade at UBS. The stock – and many others – have made big gains this year on hopes for the future of AI.
We’ll talk to the analyst behind the call, who says the transition to AI search will definitely have some growing pains.
Plus, we’ve got new developments in the battle over weight loss drugs, including promise for Eli Lilly and a setback for Pfizer. We’ll tell you all you need to know.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Power Lunch publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Power Lunch
September Rate Hike Odds, Middle East Oil Disruptions, AI Researcher Resignation...
Power Lunch
Thoma Bravo Founder, Treasury Bond Auction, Terawulf Exclusive 9/10/26
Power Lunch
Apple’s Foldable iPhone, Brent Tops $100, AT&T CEO Interview 9/9/26
Power Lunch
State of the Markets, Diesel Prices at Record Highs, Regional Bank Merger 9/8/26
Power Lunch